quantisnow
FeedTopReportsPricing
⌘K
Live feed
06:30:00·500d
PRRelease
Affimed N.V. logo

Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer

AFMD· Affimed N.V.
Health Care
Original source

Companies

  • AFMD
    Affimed N.V.
    Health Care

Recent analyst ratings

  • May 14UpdateH.C. Wainwright-
  • May 13UpdateLeerink Partners-
  • Dec 12UpdateH.C. Wainwright$6.00
  • Oct 10UpdateStifel$2.00
  • Aug 18UpdateWells Fargo-
  • Mar 31UpdatePiper Sandler$7.00

Related

  • SEC338d
    Amendment: SEC Form SCHEDULE 13G/A filed by Affimed N.V.
  • ANALYST344d
    Affimed Therapeutics downgraded by H.C. Wainwright
  • SEC344d
    SEC Form 6-K filed by Affimed N.V.
  • PR345d
    Affimed Announces Receipt of Nasdaq Delisting Notice
  • ANALYST345d
    Affimed Therapeutics downgraded by Leerink Partners
  • SEC345d
    SEC Form 6-K filed by Affimed N.V.
  • PR345d
    Affimed Announces Filing for the Opening of Insolvency Proceedings
  • SEC357d
    SEC Form NT 20-F filed by Affimed N.V.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022